Inarigivir ammonium

CAS No. 2172788-92-8

Inarigivir ammonium( ORI-9020 ammonium | SB-9200 ammonium )

Catalog No. M28733 CAS No. 2172788-92-8

Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 538 Get Quote
5MG 860 Get Quote
10MG 1161 Get Quote
25MG 1728 Get Quote
50MG 2331 Get Quote
100MG 3132 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Inarigivir ammonium
  • Note
    Research use only, not for human use.
  • Brief Description
    Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.
  • Description
    Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.(In Vitro):Inarigivir is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B.(In Vivo):Administration of 100 mg/kg/day Inarigivir (ip) significantly reduces viral DNA in the liver and shows anti-HBV activity while serum HBV DNA is not reduced. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values.
  • In Vitro
    Inarigivir (SB 9200) is active against HBV variants carrying resistance markers against all the nucleos(t)ide analogues approved for treating chronic hepatitis B.
  • In Vivo
    Inarigivir (100 mg/kg/day, ip) significantly reduces viral DNA in the liver and shows anti-HBV activity. Serum HBV DNA is not reduced in response to treatment. Inarigivir does not affect levels of HBV RNA in liver, levels of HBeAg in serum, or mean titers of HBsAg. The minimal effective dose is identified to be between 1.6 and 0.5 mg/kg/day using liver HBV DNA values. Animal Model:Mice Dosage:100 mg/kg.Administration:IP, daily.Result:Significantly reduced viral DNA in the liver and shows anti-HBV activity similar ADV positive control.
  • Synonyms
    ORI-9020 ammonium | SB-9200 ammonium
  • Pathway
    Microbiology/Virology
  • Target
    HBV
  • Recptor
    HIF/HIF Prolyl-Hydroxylase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2172788-92-8
  • Formula Weight
    604.53
  • Molecular Formula
    C20H29N8O10PS
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 100 mg/mL (165.42 mM)
  • SMILES
    NC1=C(N=CN2[C@@H]3O[C@H](COP(O[C@H]4[C@@H](OC)[C@H](N5C=CC(NC5=O)=O)O[C@@H]4CO)(S)=O)[C@@H](O)C3)C2=NC=N1.N
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Nangaku M, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol. 2007 Dec;27(12):2548-54.
molnova catalog
related products
  • GLP-26

    GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.

  • Antiviral agent

    Antiviral agent is thiazolidin-4-one with anti-hepatitis B activity

  • Vebicorvir

    Vebicorvir is a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity.